Phase II evaluation of XXXX in refractory adult @entity3052 : a Southwest Oncology Group Study.

@entity1 @entity981 @entity137 @entity390 @entity882 @entity30021 @entity4349 @entity294 @entity391 @entity33 @entity2800 @entity3052 @entity1778 @entity1431 @entity1370
@entity30021 , a new anthracycline antibiotic, was used to treat 24 adult @entity1 with @entity1778 , using a total dose of 300 mg/m2 (75 mg/m2/day X 4). There were 20 @entity1 with acute myelogenous and four with @entity981 . Approximately two-thirds of the @entity1 had a Karnofsky score of less than or equal to 2, and two-thirds had received two or more previous induction programs. Interim bone marrow evaluation was obtained in 18 of 30 remission induction courses and revealed marked hypocellularity in 14, inadequate specimens in three, and persistent disease in one. Seven @entity1 received more than one course. Two @entity1 refused further therapy. In @entity1 with @entity2800 , there were two complete remissions lasting 10 and 16 months and one partial remission lasting 4 1/2 months. There were no responders in @entity1 with @entity981 . @entity137 included profound @entity1431 and @entity882 , moderate @entity390 and @entity391 , @entity294 , and @entity33 . There were no cardiac symptoms associated with the drug infusion, but there were three late events possibly associated with @entity4349 @entity1370 . Used in this dosage schedule, @entity30021 is an active, but toxic, agent in the @entity3052 .
